Claims

1. An oligonucleotide comprising a sense strand and an antisense strand, wherein the oligonucleotide comprises

a sense strand comprising nucleotide sequence
5’ GACGCUGACCCUGAA$_m$GUUCAUCUU 3’; and
an antisense strand comprising nucleotide sequence
3’ CUG$_m$CGACUGGGACUUCAAGUAGAA 5’;

wherein the nucleotide indexed m is 2’-O-methylated.

2. The oligonucleotide of claim 1, wherein the sense strand and/or the antisense strand further comprises a phosphothioate bond, and wherein the oligonucleotide comprises

a sense strand comprising nucleotide sequence
5’ GACGCUGACCCUGAA$_m$GUUCAUCUU 3’, and
an antisense strand comprising nucleotide sequence
3’ CUG$_m$CGACUGGGACUUCAAGUAG$_{PTO}$A$_{PTO}$A 5’; or

a sense strand comprising nucleotide sequence
5’ G$_{PTO}$A$_{PTO}$CGCUGACCCUGAA$_m$GUUCAUCUU 3’, and
an antisense strand comprising nucleotide sequence
3’ CUG$_m$CGACUGGGACUUCAAGUAGAA 5’; or

a sense strand comprising nucleotide sequence
5’ G$_{PTO}$A$_{PTO}$CGCUGACCCUGAA$_m$GUUCAUCUU 3’, and
an antisense strand comprising nucleotide sequence
3’ CUG$_m$CGACUGGGACUUCAAGUAG$_{PTO}$A$_{PTO}$A 5’;

wherein
the nucleotide indexed m is 2’-O-methylated; and
the index PTO between two nucleotides indicates that said two nucleotides are

linked by a phosphothioate bond.

3. The oligonucleotide of claim 1, wherein the sense strand and the antisense strand further comprises a phosphothioate bond and a 2'-fluoro modification, and wherein the oligonucleotide comprises

a sense strand comprising nucleotide sequence
5' $G_{PTO}A_{PTO}CGCUG_fACCCUGAA_mGUUCAUCU_fU$ 3', and
an antisense strand comprising nucleotide sequence
3' $CUG_mCGACUGGGAC_fUUCAAGUAG_{PTO}A_{PTO}A$ 5'; or

a sense strand comprising nucleotide sequence
5' $G_{PTO}A_{PTO}CGCUG_fACCCUGAA_mGUUCAUC_{PTO}U_{fPTO}U$ 3', and
an antisense strand comprising nucleotide sequence
3' $CUG_mCGACUGGGAC_fUUCAAGUAG_{PTO}A_{PTO}A$ 5'; or

a sense strand comprising nucleotide sequence
5' $GACGCUG_fACCCUGAA_mGUUCAUC_{PTO}U_{fPTO}U$ 3', and
an antisense strand comprising nucleotide sequence
3' $CUG_mCGACUGGGAC_fUUCAAGUAG_{PTO}A_{PTO}A$ 5';

wherein
the nucleotide indexed m is 2'-O-methylated;
the nucleotide indexed f is 2'-fluoro; and
the index PTO between two nucleotides indicates that said two nucleotides are linked by a phosphothioate bond.

4. The oligonucleotide of any of claims 1 to 3, wherein the oligonucleotide is a RIG-I ligand.

5. A pharmaceutical composition comprising an oligonucleotide according to any of claims 1 to 3.

6. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is to be administered systemically or locally.

7. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is to be administered intraperitoneally, intramuscularly, intravenously, intranasally, subcutaneously, intradermally, or intrathecally.

8. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is to be administered intradermally.

9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is to be administered by tattooing, microneedling and/or microneedle patches.